Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: reversible

  • Revamping the Daily Pill: Research to Begin on Monthly Pill

    Although lowering side effects plays an important role in oral contraceptive compliance, one of the biggest challenges for patients is adhering to the daily schedule of the pill. Forgetting one to three pills per cycle is a frequent problem among 15-51% of users, particularly among adolescents. Lyndra Therapeutics has received a $13 million grant from the Bill & Melinda Gates Foundation and is setting out to remove the daily pill compliance challenge. The company is in early development of a monthly oral contraceptive to provide women with a discreet, noninvasive, reversible contraception option.

  • Long-Acting Reversible Contraception: Progress Made, but Challenges Remain

    In 2002, just 2.4% of U.S. women using birth control were using long-acting reversible contraceptive (LARC) methods, such as the intrauterine device or the contraceptive implant. By 2014, about 14% of women using birth control reported LARC use.

  • Training Can Help Integrate LARC Options Into Contraceptive Care

    Research from the Bixby Center for Global Reproductive Health at the University of California, San Francisco, and Planned Parenthood Federation of America indicates that a four-hour training intervention can significantly affect the likelihood that healthcare providers will integrate long-acting reversible contraceptives into their clinical care.

  • More Teens Using Contraception, Data Show

    While more relying on IUDs and other methods, pill use remains common

  • Survey results show use of LARC continues to rise

    About 46% of participants in the 2015 Contraceptive Technology Update Contraception Survey say they have seen “dramatically more” women choosing long-acting reversible contraceptive methods such as the intrauterine device and contraceptive implant in the last year.